Current status of the immunomodulation and immunomediated therapeutic strategies for multiple sclerosis

Clinical and Developmental Immunology

Volumn 2012, Issue , 2012, Pages

  Chen, Shyi Jou ^a,b   Wang, Yen Ling ^c   Fan, Hueng Chuen ^a   Lo, Wen Tsung ^a   Wang, Chih Chien ^a   Sytwu, Huey Kang ^b  

^a TRI SERVICE GENERAL HOSPITAL   (Taiwan)

^b NATIONAL DEFENSE MEDICAL CENTER   (Taiwan)

^c CHANG GUNG MEMORIAL HOSPITAL   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

ABR 215602; ALEMTUZUMAB; BETA INTERFERON; CLADRIBINE; DACLIZUMAB; ERYTHROPOIETIN; ESTRIOL; FINGOLIMOD; FUMARIC ACID; GAMMA INTERFERON; GEMFIBROZIL; GLATIRAMER; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IMMUNOMODULATING AGENT; IMMUNOSUPPRESSIVE AGENT; INTERLEUKIN 12; LAQUINIMOD; METHYLPREDNISOLONE; MINOCYCLINE; MITOXANTRONE; NATALIZUMAB; NEUROPROTECTIVE AGENT; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR AGONIST; PIOGLITAZONE; RILUZOLE; RITUXIMAB; TERIFLUNOMIDE; UNCLASSIFIED DRUG; CYTOKINE; IMMUNOLOGIC FACTOR;

ADAPTIVE IMMUNITY; ALLERGIC ENCEPHALOMYELITIS; CD4+ T LYMPHOCYTE; CLINICAL TRIAL (TOPIC); DRUG MECHANISM; HUMAN; IMMUNOCOMPETENT CELL; IMMUNOMODULATION; IMMUNOPATHOGENESIS; IMMUNOTHERAPY; MULTIPLE SCLEROSIS; NONHUMAN; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; REVIEW; TH1 CELL; TH17 CELL; ANIMAL; IMMUNOLOGY; INNATE IMMUNITY; METABOLISM; PATHOLOGY; T LYMPHOCYTE;

ANIMALS; CYTOKINES; ENCEPHALOMYELITIS, AUTOIMMUNE, EXPERIMENTAL; HUMANS; IMMUNITY, INNATE; IMMUNOLOGIC FACTORS; IMMUNOMODULATION; MULTIPLE SCLEROSIS; NEUROPROTECTIVE AGENTS; T-LYMPHOCYTES; TH17 CELLS;

EID: 84855598095     PISSN: 17402522     EISSN: 17402530     Source Type: Journal    
DOI: 10.1155/2012/970789     Document Type: Review

References (182)

1. Siffrin V., Brandt A. U., Herz J., Zipp F., New insights into adaptive immunity in chronic neuroinflammation Advances in Immunology 2007 96 1 40 (Pubitemid 350027721)
2. Beeton C., Garcia A., Chandy K. G., Induction and clinical scoring of chronic-relapsing experimental autoimmune encephalomyelitis Journal of Visualized Experiments 2007 5 224
3. Schreiner B., Heppner F. L., Becher B., Modeling multiple sclerosis in laboratory animals Seminars in Immunopathology 2009 31 4 479 495
4. Rivers T. M., Sprunt D. H., Berry G. P., Observations on attempts to produce acute disseminated encephalomyelitis in monkeys The Journal of Experimental Medicine 1933 58 1 39 53
5. Steinman L., Zamvil S. S., How to successfully apply animal studies in experimental allergic encephalomyelitis to research on multiple sclerosis Annals of Neurology 2006 60 1 12 21
6. Pette M., Fujita K., Kitze B., Whitaker J. N., Albert E., Kappos L., Wekerle H., Myelin basic protein-specific T lymphocyte lines from MS patients and healthy individuals Neurology 1990 40 11 1770 1776 (Pubitemid 20383149)
7. Schluesener H. J., Wekerle H., Autoaggressive T lymphocyte lines recognizing the encephalitogenic region of myelin basic protein: in vitro selection from unprimed rat T lymphocyte populations Journal of Immunology 1985 135 5 3128 3133 (Pubitemid 16250569)
8. Genain C. P., Lee-Parritz D., Nguyen M. H., Massacesi L., Joshi N., Ferrante R., Hoffman K., Moseley M., Letvin N. L., Hauser S. L., In healthy primates, circulating autoreactive T cells mediate autoimmune disease Journal of Clinical Investigation 1994 94 3 1339 1345 (Pubitemid 24286481)
9. Ben-Nun A., Wekerle H., Cohen I. R., The rapid isolation of clonable antigen-specific T lymphocyte lines capable of mediating autoimmune encephalomyelitis European Journal of Immunology 1981 11 3 195 199 (Pubitemid 11104096)
10. Fort M. M., Cheung J., Yen D., Li J., Zurawski S. M., Lo S., Menon S., Clifford T., Hunte B., Lesley R., Muchamuel T., Hurst S. D., Zurawski G., Leach M. W., Gorman D. M., Rennick D. M., IL-25 Induces IL-4, IL-5, and IL-13 and Th2-associated pathologies in vivo Immunity 2001 15 6 985 995 (Pubitemid 34075378)
11. Kuchroo V. K., Anderson A. C., Waldner H., Munder M., Bettelli E., Nicholson L. B., T cell response in experimental autoimmune encephalomyelitis (EAE): role of self and cross-reactive antigens in shaping, tuning, and regulating the autopathogenic T cell repertoire Annual Review of Immunology 2002 20 101 123 (Pubitemid 34293422)
12. Anderson A. C., Nicholson L. B., Legge K. L., Turchin V., Zaghouani H., Kuchroo V. K., High frequency of autoreactive myelin proteolipid protein-specific T cells in the periphery of naive mice: mechanisms of selection of the self-reactive repertoire Journal of Experimental Medicine 2000 191 5 761 770
13. Imam S. A., Guyton M. K., Haque A., Vandenbark A., Tyor W. R., Ray S. K., Banik N. L., Increased calpain correlates with Th1 cytokine profile in PBMCs from MS patients Journal of Neuroimmunology 2007 190 1-2 139 145
14. Panitch H. S., Hirsch R. L., Schindler J., Johnson K. P., Treatment of multiple sclerosis with gamma interferon: exacerbations associated with activation of the immune system Neurology 1987 37 7 1097 1102 (Pubitemid 17123439)
15. Neukirch F., Lyon-Caen O., Clanet M., Bousquet J., Feingold J., Druet P., Asthma, nasal allergies, and multiple sclerosis Journal of Allergy and Clinical Immunology 1997 99 2 270 271
16. Ando D. G., Clayton J., Kono D., Urban J. L., Sercarz E. E., Encephalitogenic T cells in the B10.PL model of experimental allergic encephalomyelitis (EAE) are of the Th-1 lymphokine subtype Cellular Immunology 1989 124 1 132 143 (Pubitemid 20000271)
17. Zamvil S. S., Steinman L., The T lymphocyte in experimental allergic encephalomyelitis Annual Review of Immunology 1990 8 579 621 (Pubitemid 20135640)
18. Yura M., Takahashi I., Serada M., Koshio T., Nakagami K., Yuki Y., Kiyono H., Role of MOG-stimulated th1 type light up (GFP+) CD4+ T cells for the development of experimental autoimmune encephalomyelitis (EAE) Journal of Autoimmunity 2001 17 1 17 25 (Pubitemid 32751878)
19. Mosmann T. R., Coffman R. L., TH1 and TH2 cells: different patterns of lymphokine secretion lead to different functional properties Annual Review of Immunology 1989 7 145 173 (Pubitemid 19138011)
20. Adorini L., Guéry J. C., Trembleau S., Manipulation of the Th1/Th2 cell balance: an approach to treat human autoimmune diseases? Autoimmunity 1996 23 1 53 68 (Pubitemid 26335835)
21. Krakowski M., Owens T., Interferon- confers resistance to experimental allergic encephalomyelitis European Journal of Immunology 1996 26 7 1641 1646 (Pubitemid 26230015)
22. Tran E. H., Prince E. N., Owens T., IFN- shapes immune invasion of the central nervous system via regulation of chemokines Journal of Immunology 2000 164 5 2759 2768 (Pubitemid 30115510)
23. Gran B., Zhang G. X., Yu S., Li J., Chen X. H., Ventura E. S., Kamoun M., Rostami A., IL-12p35-deficient mice are susceptible to experimental autoimmune encephalomyelitis: evidence for redundancy in the IL-12 system in the induction of central nervous system autoimmune demyelination Journal of Immunology 2002 169 12 7104 7110 (Pubitemid 36899299)
24. Zhang G. X., Gran B., Yu S., Li J., Siglienti I., Chen X., Kamoun M., Rostami A., Induction of experimental autoimmune encephalomyelitis in IL-12 receptor- 2-deficient mice: IL-12 responsiveness is not required in the pathogenesis of inflammatory demyelination in the central nervous system Journal of Immunology 2003 170 4 2153 2160 (Pubitemid 36197439)
25. Gutcher I., Urich E., Wolter K., Prinz M., Becher B., Interleukin 18-independent engagement of interleukin 18 receptor- is required for autoimmune inflammation Nature Immunology 2006 7 9 946 953 (Pubitemid 44263908)
26. Ferber I. A., Brocke S., Taylor-Edwards C., Ridgway W., Dinisco C., Steinman L., Dalton D., Fathman C. G., Mice with a disrupted IFN- gene are susceptible to the induction of experimental autoimmune encephalomyelitis (EAE) Journal of Immunology 1996 156 1 5 7
27. Oppmann B., Lesley R., Blom B., Timans J. C., Xu Y., Hunte B., Vega F., Yu N., Wang J., Singh K., Zonin F., Vaisberg E., Churakova T., Liu M. R., Gorman D., Wagner J., Zurawski S., Liu Y. J., Abrams J. S., Moore K. W., Rennick D., De Waal-Malefyt R., Hannum C., Bazan J. F., Kastelein R. A., Novel p19 protein engages IL-12p40 to form a cytokine, IL-23, with biological activities similar as well as distinct from IL-12 Immunity 2000 13 5 715 725
28. Cua D. J., Sherlock J., Chen Y., Murphy C. A., Joyce B., Seymour B., Lucian L., To W., Kwan S., Churakova T., Zurawski S., Wiekowski M., Lira S. A., Gorman D., Kastelein R. A., Sedgwick J. D., Interleukin-23 rather than interleukin-12 is the critical cytokine for autoimmune inflammation of the brain Nature 2003 421 6924 744 748 (Pubitemid 36227625)
29. Aggarwal S., Ghilardi N., Xie M. H., De Sauvage F. J., Gurney A. L., Interleukin-23 promotes a distinct CD4 T cell activation state characterized by the production of interleukin-17 Journal of Biological Chemistry 2003 278 3 1910 1914 (Pubitemid 36801431)
30. Langrish C. L., Chen Y., Blumenschein W. M., Mattson J., Basham B., Sedgwick J. D., McClanahan T., Kastelein R. A., Cua D. J., IL-23 drives a pathogenic T cell population that induces autoimmune inflammation Journal of Experimental Medicine 2005 201 2 233 240 (Pubitemid 40189432)
31. Park H., Li Z., Yang X. O., Chang S. H., Nurieva R., Wang Y. H., Wang Y., Hood L., Zhu Z., Tian Q., Dong C., A distinct lineage of CD4 T cells regulates tissue inflammation by producing interleukin 17 Nature Immunology 2005 6 11 1133 1141 (Pubitemid 41541791)
32. Harrington L. E., Hatton R. D., Mangan P. R., Turner H., Murphy T. L., Murphy K. M., Weaver C. T., Interleukin 17-producing CD4+ effector T cells develop via a lineage distinct from the T helper type 1 and 2 lineages Nature Immunology 2005 6 11 1123 1132 (Pubitemid 41541790)
33. Dong C., Diversification of T-helper-cell lineages: finding the family root of IL-17-producing cells Nature Reviews Immunology 2006 6 4 329 333
34. Miossec P., Korn T., Kuchroo V. K., Interleukin-17 and type 17 helper T cells The New England Journal of Medicine 2009 361 9 848 898
35. Annunziato F., Cosmi L., Santarlasci V., Maggi L., Liotta F., Mazzinghi B., Parente E., Fil L., Ferri S., Frosali F., Giudici F., Romagnani P., Parronchi P., Tonelli F., Maggi E., Romagnani S., Phenotypic and functional features of human Th17 cells Journal of Experimental Medicine 2007 204 8 1849 1861 (Pubitemid 47240944)
36. Hedegaard C. J., Krakauer M., Bendtzen K., Lund H., Sellebjerg F., Nielsen C. H., T helper cell type 1 (Th1), Th2 and Th17 responses to myelin basic protein and disease activity in multiple sclerosis Immunology 2008 125 2 161 169
37. Parham C., Chirica M., Timans J., Vaisberg E., Travis M., Cheung J., Pflanz S., Zhang R., Singh K. P., Vega F., To W., Wagner J., O'Farrell A. M., McClanahan T., Zurawski S., Hannum C., Gorman D., Rennick D. M., Kastelein R. A., De Waal Malefyt R., Moore K. W., A receptor for the heterodimeric cytokine IL-23 is composed of IL-12R 1 and a novel cytokine receptor subunit, IL-23R Journal of Immunology 2002 168 11 5699 5708 (Pubitemid 34556153)
38. Mangan P. R., Harrington L. E., O'Quinn D. B., Helms W. S., Bullard D. C., Elson C. O., Hatton R. D., Wahl S. M., Schoeb T. R., Weaver C. T., Transforming growth factor- induces development of the T H17 lineage Nature 2006 441 7090 231 234
39. Bettelli E., Carrier Y., Gao W., Korn T., Strom T. B., Oukka M., Weiner H. L., Kuchroo V. K., Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells Nature 2006 441 7090 235 238
40. Yang L., Anderson D. E., Baecher-Allan C., Hastings W. D., Bettelli E., Oukka M., Kuchroo V. K., Hafler D. A., IL-21 and TGF- are required for differentiation of human T H17 cells Nature 2008 454 7202 350 352
41. Korn T., Bettelli E., Gao W., Awasthi A., Jger A., Strom T. B., Oukka M., Kuchroo V. K., IL-21 initiates an alternative pathway to induce proinflammatory T H17 cells Nature 2007 448 7152 484 487 (Pubitemid 47123515)
42. Lock C., Hermans G., Pedotti R., Brendolan A., Schadt E., Garren H., Langer-Gould A., Strober S., Cannella B., Allard J., Klonowski P., Austin A., Lad N., Kaminski N., Galli S. J., Oksenberg J. R., Raine C. S., Heller R., Steinman L., Gene-microarray analysis of multiple sclerosis lesions yields new targets validated in autoimmune encephalomyelitis Nature Medicine 2002 8 5 500 508 (Pubitemid 34546753)
43. Korn T., Bettelli E., Oukka M., Kuchroo V. K., IL-17 and Th17 cells Annual Review of Immunology 2009 27 485 517
44. Chen Z., O'Shea J. J., Th17 cells: a new fate for differentiating helper T cells Immunologic Research 2008 41 2 87 102
45. Lovett-Racke A. E., Rocchini A. E., Choy J., Northrop S. C., Hussain R. Z., Ratts R. B., Sikder D., Racke M. K., Silencing T-bet defines a critical role in the differentiation of autoreactive T lymphocytes Immunity 2004 21 5 719 731 (Pubitemid 39487893)
46. Ouyang W., Ranganath S. H., Weindel K., Bhattacharya D., Murphy T. L., Sha W. C., Murphy K. M., Inhibition of Th1 development mediated by GATA-3 through an IL-4- independent mechanism Immunity 1998 9 5 745 755 (Pubitemid 28557602)
47. Ouyang W., Lhning M., Gao Z., Assenmacher M., Ranganath S., Radbruch A., Murphy K. M., Stat6-independent GATA-3 autoactivation directs IL-4-independent Th2 development and commitment Immunity 2000 12 1 27 37 (Pubitemid 30069212)
48. Bettelli E., Sullivan B., Szabo S. J., Sobel R. A., Glimcher L. H., Kuchroo V. K., Loss of T-bet, but not STAT1, prevents the development of experimental autoimmune encephalomyelitis Journal of Experimental Medicine 2004 200 1 79 87 (Pubitemid 38924730)
49. O'Connor R. A., Prendergast C. T., Sabatos C. A., Lau C. W. Z., Leech M. D., Wraith D. C., Anderton S. M., Cutting edge: Th1 cells facilitate the entry of Th17 cells to the central nervous system during experimental autoimmune encephalomyelitis Journal of Immunology 2008 181 6 3750 3754
50. Edwards L. J., Robins R. A., Constantinescu C. S., Th17/Th1 phenotype in demyelinating disease Cytokine 2010 50 1 19 23
51. Pai S. Y., Truitt M. L., Ho I. C., GATA-3 deficiency abrogates the development and maintenance of T helper type 2 cells Proceedings of the National Academy of Sciences of the United States of America 2004 101 7 1993 1998 (Pubitemid 38229003)
52. Ivanov I. I., McKenzie B. S., Zhou L., Tadokoro C. E., Lepelley A., Lafaille J. J., Cua D. J., Littman D. R., The orphan nuclear receptor ROR t directs the differentiation program of proinflammatory IL-17+ T helper cells Cell 2006 126 6 1121 1133 (Pubitemid 44380299)
53. Fontenot J. D., Gavin M. A., Rudensky A. Y., Foxp3 programs the development and function of CD4+CD25+ regulatory T cells Nature Immunology 2003 4 4 330 336 (Pubitemid 36432314)
54. Hirota K., Martin B., Veldhoen M., Development, regulation and functional capacities of Th17 cells Seminars in Immunopathology 2010 32 1 3 16
55. Lopez-Diego R. S., Weiner H. L., Novel therapeutic strategies for multiple sclerosisa multifaceted adversary Nature Reviews Drug Discovery 2008 7 11 909 925
56. Matusevicius D., Kiviskk P., He B., Kostulas N., zenci V., Fredrikson S., Link H., Interleukin-17 mRNA expression in blood and CSF mononuclear cells is augmented in multiple sclerosis Multiple Sclerosis 1999 5 2 101 104 (Pubitemid 29186827)
57. Ransohoff R. M., Kiviskk P., Kidd G., Three or more routes for leukocyte migration into the central nervous system Nature Reviews Immunology 2003 3 7 569 581 (Pubitemid 37328676)
58. Xiao B. G., Diab A., Zhu J., Van Der Meide P., Link H., Astrocytes induce hyporesponses of myelin basic protein-reactive T and B cell function Journal of Neuroimmunology 1998 89 1-2 113 121 (Pubitemid 28389583)
59. Dijkstra C. D., De Groot C. J. A., Huitinga I., The role of macrophages in demyelination Journal of Neuroimmunology 1992 40 2-3 183 188
60. Kasper L. H., Shoemaker J., Multiple sclerosis immunology: the healthy immune system vs the MS immune system Neurology 2010 74 S2 S8
61. Deshpande P., King I. L., Segal B. M., Cutting edge: CNS CD11c+ cells, from mice with encephalomyelitis polarize Th17 cells, and support CD25+CD4+ T cell-mediated immunosuppression, suggesting dual roles in the disease process Journal of Immunology 2007 178 11 6695 6699 (Pubitemid 46847389)
62. Cserr H. F., Knopf P. M., Cervical lymphatics, the blood-brain barrier and the immunoreactivity of the brain: a new view Immunology Today 1992 13 12 507 512
63. Hemmer B., Nessler S., Zhou D., Kieseier B., Hartung H. P., Immunopathogenesis and immunotherapy of multiple sclerosis Nature Clinical Practice Neurology 2006 2 4 201 211
64. Neumann H., Cavalie A., Jenne D. E., Wekerle H., Induction of MHC class I genes in neurons Science 1995 269 5223 549 552
65. Dandekar A. A., Wu G. F., Pewe L., Perlman S., Axonal damage is T cell mediated and occurs concomitantly with demyelination in mice infected with a neurotropic coronavirus Journal of Virology 2001 75 13 6115 6120 (Pubitemid 32553142)
66. Probert L., Eugster H. P., Akassoglu K., Bauer J., Frei K., Lassmann H., Fontana A., TNFR1 signalling is critical for the development of demyelination and the limitation of T-cell responses during immune-mediated CNS disease Brain 2000 123 10 2005 2019
67. Tzartos J. S., Friese M. A., Craner M. J., Palace J., Newcombe J., Esiri M. M., Fugger L., Interleukin-17 production in central nervous system-infiltrating T cells and glial cells is associated with active disease in multiple sclerosis American Journal of Pathology 2008 172 1 146 155 (Pubitemid 351186376)
68. Crome S. Q., Wang A. Y., Kang C. Y., Levings M. K., The role of retinoic acid-related orphan receptor variant 2 and IL-17 in the development and function of human CD4+ T cells European Journal of Immunology 2009 39 6 1480 1493
69. Li Y., Chu N., Hu A., Gran B., Rostami A., Zhang G. X., Increased IL-23p19 expression in multiple sclerosis lesions and its induction in microglia Brain 2007 130 2 490 501 (Pubitemid 46181102)
70. Kebir H., Kreymborg K., Ifergan I., Dodelet-Devillers A., Cayrol R., Bernard M., Giuliani F., Arbour N., Becher B., Prat A., Human TH17 lymphocytes promote blood-brain barrier disruption and central nervous system inflammation Nature Medicine 2007 13 10 1173 1175 (Pubitemid 47530640)
71. Linker R. A., Lhder F., Kallen K. J., Lee D. H., Engelhardt B., Rose-John S., Gold R., IL-6 transsignalling modulates the early effector phase of EAE and targets the blood-brain barrier Journal of Neuroimmunology 2008 205 1-2 64 72
72. Ifergan I., Kébir H., Bernard M., Wosik K., Dodelet-Devillers A., Cayrol R., Arbour N., Prat A., The blood-brain barrier induces differentiation of migrating monocytes into Th17-polarizing dendritic cells Brain 2008 131 3 785 799 (Pubitemid 351294709)
73. Miljkovic D., Momcilovic M., Stojanovic I., Stosic-Grujicic S., Ramic Z., Mostarica-Stojkovic M., Astrocytes stimulate interleukin-17 and interferon- production in vitro Journal of Neuroscience Research 2007 85 16 3598 3606 (Pubitemid 350228705)
74. Das Sarma J., Ciric B., Marek R., Sadhukhan S., Caruso M. L., Shafagh J., Fitzgerald D. C., Shindler K. S., Rostami A. M., Functional interleukin-17 receptor A is expressed in central nervous system glia and upregulated in experimental autoimmune encephalomyelitis Journal of Neuroinflammation 2009 6, article 14
75. Ma X., Reynolds S. L., Baker B. J., Li X., Benveniste E. N., Qin H., IL-17 enhancement of the IL-6 signaling cascade in astrocytes Journal of Immunology 2010 184 9 4898 4906
76. Kang Z., Altuntas C. Z., Gulen M. F., Liu C., Giltiay N., Qin H., Liu L., Qian W., Ransohoff R. M., Bergmann C., Stohlman S., Tuohy V. K., Li X., Astrocyte-restricted ablation of interleukin-17-induced act1-mediated signaling ameliorates autoimmune encephalomyelitis Immunity 2010 32 3 414 425
77. Merkler D., Bscke R., Schmelting B., Czéh B., Fuchs E., Brck W., Stadelmann C., Differential macrophage/microglia activation in neocortical EAE lesions in the marmoset monkey Brain Pathology 2006 16 2 117 123 (Pubitemid 43876471)
78. Lees J. R., Iwakura Y., Russell J. H., Host T cells are the main producers of IL-17 within the central nervous system during initiation of experimental autoimmune encephalomyelitis induced by adoptive transfer of Th1 cell lines Journal of Immunology 2008 180 12 8066 8072
79. Sutton C., Brereton C., Keogh B., Mills K. H. G., Lavelle E. C., A crucial role for interleukin (IL)-1 in the induction of IL-17-producing T cells that mediate autoimmune encephalomyelitis Journal of Experimental Medicine 2006 203 7 1685 1691 (Pubitemid 44036274)
80. De Jong B. A., Huizinga T. W. J., Bollen E. L. E. M., Uitdehaag B. M. J., Bosma G. P. T., Van Buchem M. A., Remarque E. J., Burgmans A. C. S., Kalkers N. F., Polman C. H., Westendorp R. G. J., Production of IL-1 and IL-1Ra as risk factors for susceptibility and progression of relapse-onset multiple sclerosis Journal of Neuroimmunology 2002 126 1-2 172 179 (Pubitemid 34521742)
81. Broberg E. K., Salmi A. A., Hukkanen V., IL-4 is the key regulator in herpes simplex virus-based gene therapy of BALB/c experimental autoimmune encephalomyelitis Neuroscience Letters 2004 364 3 173 178 (Pubitemid 38757927)
82. Haas J., Hug A., Viehver A., Fritzsching B., Falk C. S., Filser A., Vetter T., Milkova L., Korporal M., Fritz B., Storch-Hagenlocher B., Krammer P. H., Suri-Payer E., Wildemann B., Reduced suppressive effect of CD4+CD25high regulatory T cells on the T cell immune response against myelin oligodendrocyte glycoprotein in patients with multiple sclerosis European Journal of Immunology 2005 35 11 3343 3352 (Pubitemid 41672538)
83. Singh S. P., Zhang H. H., Foley J. F., Hedrick M. N., Farber J. M., Human T cells that are able to produce IL-17 express the chemokine receptor CCR6 Journal of Immunology 2008 180 1 214 221
84. Haak S., Croxford A. L., Kreymborg K., Heppner F. L., Pouly S., Becher B., Waisman A., IL-17A and IL-17F do not contribute vitally to autoimmune neuro-inflammation in mice Journal of Clinical Investigation 2009 119 1 61 69
85. Liu X., Yun S. L., Yu C. R., Egwuagu C. E., Loss of STAT3 in CD4+ T cells prevents development of experimental autoimmune diseases Journal of Immunology 2008 180 9 6070 6076
86. Stromnes I. M., Cerretti L. M., Liggitt D., Harris R. A., Goverman J. M., Differential regulation of central nervous system autoimmunity by T H1 and TH17 cells Nature Medicine 2008 14 3 337 342 (Pubitemid 351347910)
87. Zhou L., Ivanov I. I., Spolski R., Min R., Shenderov K., Egawa T., Levy D. E., Leonard W. J., Littman D. R., IL-6 programs TH-17 cell differentiation by promoting sequential engagement of the IL-21 and IL-23 pathways Nature Immunology 2007 8 9 967 974 (Pubitemid 47300011)
88. Zhang Z., Rosenbaum J. T., Zhong W., Lim C., Hinrichs D. J., Costimulation of Th17 cells: adding fuel or putting out the fire in the inflamed gut? Seminars in Immunopathology 2010 32 1 55 70
89. Vollmer T. L., Liu R., Price M., Rhodes S., La Cava A., Shi F. D., Differential effects of IL-21 during initiation and progression of autoimmunity against neuroantigen Journal of Immunology 2005 174 5 2696 2701 (Pubitemid 40279684)
90. Pot C., Jin H., Awasthi A., Liu S. M., Lai C. Y., Madan R., Sharpe A. H., Karp C. L., Miaw S. C., Ho I. C., Kuchroo V. K., Cutting edge: IL-27 induces the transcription factor c-Maf, cytokine IL-21, and the costimulatory receptor ICOS that coordinately act together to promote differentiation of IL-10-producing Tr1 cells Journal of Immunology 2009 183 2 797 801
91. Fitzgerald D. C., Ciric B., Touil T., Harle H., Grammatikopolou J., Das Sarma J., Gran B., Zhang G. X., Rostami A., Suppressive effect of IL-27 on encephalitogenic Th17 cells and the effector phase of experimental autoimmune encephalomyelitis Journal of Immunology 2007 179 5 3268 3275
92. Jger A., Dardalhon V., Sobel R. A., Bettelli E., Kuchroo V. K., Th1, Th17, and Th9 effector cells induce experimental autoimmune encephalomyelitis with different pathological phenotypes Journal of Immunology 2009 183 11 7169 7177
93. Mueller A. M., Pedré X., Killian S., David M., Steinbrecher A., The Decoy Receptor 3 (DcR3, TNFRSF6B) suppresses Th17 immune responses and is abundant in human cerebrospinal fluid Journal of Neuroimmunology 2009 209 1-2 57 64
94. Nowak E. C., Weaver C. T., Turner H., Begum-Haque S., Becher B., Schreiner B., Coyle A. J., Kasper L. H., Noelle R. J., IL-9 as a mediator of Th17-driven inflammatory disease Journal of Experimental Medicine 2009 206 8 1653 1660
95. Wiendl H., Toyka K. V., Rieckmann P., Gold R., Hartung H. P., Hohlfeld R., Baumhackl U., Berger T., Deisenhammer F., Fazekas F., Freimller M., Kollegger H., Kristoferitsch W., Lassmann H., Markut H., Strasser-Fuchs S., Vass K., Sindic C., D'hooghe M. B., Podobnik S., Havrdova E., Elovaara I., Clanet M., Confavreux C., Edan G., Lubetzki C., Altenkirch H., Bamborschke S., Baum K., Bayas A., Benecke R., Brck W., Buttmann M., Chan A., Daumer M., Dommasch D., Elias W. G., Fasshauer E., Flachenecker P., Haas J., Haferkamp G., Haller P., Heesen C., Heibel M., Heidenreich F., Hemmer B., Henze T., Janzen R. W. C., Japp G., Jung S., Jgelt E., Kallmann B., Kieseier B. C., Kleinschnitz C., Khler J., Khler W., Klmel W., Knig N., Lehrieder G., Leussink V., Lowitzsch K., Murer M., Manegold U., Melms A., Mertin J., Meuth S. G., Neuhaus O., Oschmann P., Petereit H. F., Pette M., Phlau D., Pohl D., Ruprecht K., Sailer M., Schipper H., Schmidt S., Schock G., Schulz M., Schwarz S., Schwendemann G., Seidel D., Sommer N., Stangel M., Stark E., Steinbrecher A., Stoll G., Tumani H., Voltz R., Weber F., Weilbach F., Wiethlter H., Wildemann B., Zettl U. K., Ziemssen T., Zipp F., Zschenderlein R., Orologas A., Guseo A., Bergmann S., Pugliatti M., Myhr K. M., Izquierdo G., Bassetti C., Beer K., Beer S., Buettner U., Chofflon M., Gass A., Goebels N., Gtschi-Fuchs M., Kappos L., Kesselring J., Ludin H. P., Mattle H., Schluep M., Vaney C., Bates D., Basic and escalating immunomodulatory treatments in multiple sclerosis: current therapeutic recommendations Journal of Neurology 2008 255 10 1449 1463
96. Goodin D. S., Frohman E. M., Garmany G. P., Halper J., Likosky W. H., Lublin F. D., Silberberg D. H., Stuart W. H., Van Den Noort S., Disease modifying therapies in multiple sclerosis: report of the therapeutics and technology assessment subcommittee of the American academy of neurology and the MS council for clinical practice guidelines Neurology 2002 58 2 169 178 (Pubitemid 34086933)
97. Henze T., Rieckmann P., Toyka K. V., Symptomatic treatment of multiple sclerosis: multiple Sclerosis Therapy Consensus Group (MSTCG) of the German Multiple Sclerosis Society European Neurology 2006 56 2 78 105 (Pubitemid 44492163)
98. Hemmer B., Hartung H. P., Toward the development of rational therapies in multiple sclerosis: what is on the horizon? Annals of Neurology 2007 62 4 314 326 (Pubitemid 350105946)
99. Bielekova B., Becker B. L., Monoclonal antibodies in MS: mechanisms of action Neurology 2010 74 S31 S40
100. Bates D., Alemtuzumab International MS journal/MS Forum 2009 16 3 75 76
101. Hawker K., O'Connor P., Freedman M. S., Calabresi P. A., Antel J., Simon J., Hauser S., Waubant E., Vollmer T., Panitch H., Zhang J., Chin P., Smith C. H., Rituximab in patients with primary progressive multiple sclerosis: results of a randomized double-blind placebo-controlled multicenter trial Annals of Neurology 2009 66 4 460 471
102. Bielekova B., Howard T., Packer A. N., Richert N., Blevins G., Ohayon J., Waldmann T. A., McFarland H. F., Martin R., Effect of anti-CD25 antibody daclizumab in the inhibition of inflammation and stabilization of disease progression in multiple sclerosis Archives of Neurology 2009 66 4 483 489
103. Dhib-Jalbut S., Mechanisms of action of interferons and glatiramer acetate in multiple sclerosis Neurology 2002 58 8 S3 S9
104. Krakauer M., Sorensen P., Khademi M., Olsson T., Sellebjerg F., Increased IL-10 mRNA and IL-23 mRNA expression in multiple sclerosis: interferon- treatment increases IL-10 mRNA expression while reducing IL-23 mRNA expression Multiple Sclerosis 2008 14 5 622 630 (Pubitemid 351954404)
105. Ramgolam V. S., Sha Y., Jin J., Zhang X., Markovic-Plese S., IFN- inhibits human Th17 cell differentiation Journal of Immunology 2009 183 8 5418 5427
106. Guo B., Chang E. Y., Cheng G., The type I IFN induction pathway constrains Th17-mediated autoimmune inflammation in mice Journal of Clinical Investigation 2008 118 5 1680 1690 (Pubitemid 351632372)
107. Sweeney C. M., Lonergan R., Basdeo S. A., Kinsella K., Dungan L. S., Higgins S. C., Kelly P. J., Costelloe L., Tubridy N., Mills K. H.G., Fletcher J. M., IL-27 mediates the response to IFN- therapy in multiple sclerosis patients by inhibiting Th17 cells Brain, Behavior and Immunity 2011 25 6 1170 1181
108. Galligan C. L., Pennell L. M., Murooka T. T., Baig E., Majchrzak-Kita B., Rahbar R., Fish E. N., Interferon- is a key regulator of proinflammatory events in experimental autoimmune encephalomyelitis Multiple Sclerosis 2010 16 12 1458 1473
109. Axtell R. C., De Jong B. A., Boniface K., Van Der Voort L. F., Bhat R., De Sarno P., Naves R., Han M., Zhong F., Castellanos J. G., Mair R., Christakos A., Kolkowitz I., Katz L., Killestein J., Polman C. H., De Waal Malefyt R., Steinman L., Raman C., T helper type 1 and 17 cells determine efficacy of interferon- in multiple sclerosis and experimental encephalomyelitis Nature Medicine 2010 16 4 406 412
110. Axtell R. C., Raman C., Steinman L., Interferon- exacerbates Th17-mediated inflammatory disease Trends in Immunology 2011 32 6 272 277
111. Antel J., Bar-Or A., Roles of immunoglobulins and B cells in multiple sclerosis: from pathogenesis to treatment Journal of Neuroimmunology 2006 180 1-2 3 8 (Pubitemid 44692323)
112. Fillatreau S., Gray D., Anderton S. M., Not always the bad guys: B cells as regulators of autoimmune pathology Nature Reviews Immunology 2008 8 5 391 397 (Pubitemid 351595221)
113. Ramgolam V. S., Sha Y., Marcus K. L., Choudhary N., Troiani L., Chopra M., Markovic-Plese S., B cells as a therapeutic target for IFN- in relapsing-remitting multiple sclerosis Journal of Immunology 2011 186 7 4518 4526
114. Valenzuela R. M., Costello K., Chen M., Said A., Johnson K. P., Dhib-Jalbut S., Clinical response to glatiramer acetate correlates with modulation of IFN- and IL-4 expression in multiple sclerosis Multiple Sclerosis 2007 13 6 754 762 (Pubitemid 47074099)
115. Saresella M., Marventano I., Longhi R., Lissoni F., Trabattoni D., Mendozzi L., Caputo D., Clerici M., CD4+CD25+FoxP3+PD1- Regulatory T cells in acute and stable relapsing-remitting multiple sclerosis and their modulation by therapy FASEB Journal 2008 22 10 3500 3508
116. Hong J., Li N., Zhang X., Zheng B., Zhang J. Z., Induction of CD4+CD25+ regulatory T cells by copolymer-I through activation of transcription factor Foxp3 Proceedings of the National Academy of Sciences of the United States of America 2005 102 18 6449 6454 (Pubitemid 40617463)
117. Vieira P. L., Heystek H. C., Wormmeester J., Wierenga E. A., Kapsenberg M. L., Glatiramer acetate (copolymer-1, copaxone) promotes Th2 cell development and increased IL-10 production through modulation of dendritic cells Journal of Immunology 2003 170 9 4483 4488 (Pubitemid 36519953)
118. Jung S., Siglienti I., Grauer O., Magnus T., Scarlato G., Toyka K., Induction of IL-10 in rat peritoneal macrophages and dendritic cells by glatiramer acetate Journal of Neuroimmunology 2004 148 1-2 63 73 (Pubitemid 38229559)
119. Elovaara I., Ukkonen M., Leppkynns M., Lehtimki T., Luomala M., Peltola J., Dastidar P., Adhesion molecules in multiple sclerosis: relation to subtypes of disease and methylprednisolone therapy Archives of Neurology 2000 57 4 546 551 (Pubitemid 30212129)
120. Elovaara I., Lll M., Spare E., Lehtimki T., Dastidar P., Methylprednisolone reduces adhesion molecules in blood and cerebrospinal fluid in patients with MS Neurology 1998 51 6 1703 1708 (Pubitemid 28565256)
121. Theien B. E., Vanderlugt C. L., Eagar T. N., Nickerson-Nutter C., Nazareno R., Kuchroo V. K., Miller S. D., Discordant effects of anti-VLA-4 treatment before and after onset of relapsing experimental autoimmune encephalomyelitis Journal of Clinical Investigation 2001 107 8 995 1006 (Pubitemid 32323409)
122. Stve O., Marra C. M., Jerome K. R., Cook L., Cravens P. D., Cepok S., Frohman E. M., Phillips T., Arendt G., Hemmer B., Monson N. L., Racke M. K., Immune surveillance in multiple sclerosis patients treated with natalizumab Annals of Neurology 2006 59 5 743 747 (Pubitemid 43673151)
123. Langer-Gould A., Atlas S. W., Green A. J., Bollen A. W., Pelletier D., Progressive multifocal leukoencephalopathy in a patient treated with natalizumab The New England Journal of Medicine 2005 353 4 375 381 (Pubitemid 41132342)
124. Kleinschmidt-DeMasters B. K., Tyler K. L., Progressive multifocal leukoencephalopathy complicating treatment with natalizumab and interferon -1a for multiple sclerosis The New England Journal of Medicine 2005 353 4 369 374 (Pubitemid 41132341)
125. Hellwig K., Gold R., Progressive multifocal leukoencephalopathy and natalizumab Journal of Neurology 2011 258 11 1920 1928
126. Gorelik L., Lerner M., Bixler S., Crossman M., Schlain B., Simon K., Pace A., Cheung A., Chen L. L., Berman M., Zein F., Wilson E., Yednock T., Sandrock A., Goelz S. E., Subramanyam M., Anti-JC virus antibodies: implications for PML risk stratification Annals of Neurology 2010 68 3 295 303
127. Richard R., New risk data on PML puts hard numbers on antibody status, immunosuppressants, and treatment duration Neurology Today 2011 11 14 8
128. Warnke C., Menge T., Hartung H. P., Racke M. K., Cravens P. D., Bennett J. L., Frohman E. M., Greenberg B. M., Zamvil S. S., Gold R., Hemmer B., Kieseier B. C., Stve O., Natalizumab and progressive multifocal leukoencephalopathy: what are the causal factors and can it be avoided? Archives of Neurology 2010 67 8 923 930
129. Hartung H. P., Gonsette R., Knig N., Kwiecinski H., Guseo A., Morrissey S. P., Krapf H., Zwingers T., Albrecht H., Basedow-Rajwich B., Hofmeister R., Pllmann W., Starck M., Beer K., Hopf H. C., Khler J., Lensch E., Besinger U., Vom Dahl M., Hendrich A., Lser M., Braun M., Greiling H. W., Greve H., Kohl D., Merkel M., Conrad B., Konstanzer A., Kornhuber M., Dierkes W., Munz T., Zenker O., Flachenecker P. M., Weilbach F. X., Haas J., Hauser U., Kmpf D., Moser A., Scholz J., Weigle L. J., Branas C., Sadzot B., Cras P., Dams L., Vande Gaer L., Demonty L., Lissoir F., Guillaume D., Seeldrayers P., Peeters B., Hosszu Z., Jofej E., Janiec K., Lubos L., Waigt A., Kaminska A. M., Zakrzewska-Pniewska B., Mitoxantrone in progressive multiple sclerosis: a placebo-controlled, double-blind, randomised, multicentre trial The Lancet 2002 360 9350 2018 2025 (Pubitemid 36026580)
130. Vogelgesang A., Rosenberg S., Skrzipek S., Brker B. M., Dressel A., Mitoxantrone treatment in multiple sclerosis induces TH2-type cytokines Acta Neurologica Scandinavica 2010 122 4 237 243
131. Hohlfeld R., Multiple sclerosis: cladribine-a contentious therapeutic contender for MS Nature Reviews Neurology 2011 7 8 425 427
132. Matloubian M., Lo C. G., Cinamon G., Lesneski M. J., Xu Y., Brinkmann V., Allende M. L., Proia R. L., Cyster J. G., Lymphocyte egress from thymus and peripheral lymphoid organs is dependent on S1P receptor 1 Nature 2004 427 6972 355 360 (Pubitemid 38133663)
133. Ehling R., Berger T., Reindl M., Multiple sclerosisestablished and novel therapeutic approaches Central Nervous System Agents in Medicinal Chemistry 2010 10 1 3 15
134. Strader C. R., Pearce C. J., Oberlies N. H., Fingolimod (FTY720): a recently approved multiple sclerosis drug based on a fungal secondary metabolite Journal of Natural Products 2011 74 4 900 907
135. Lim S. Y., Constantinescu C. S., Current and future disease-modifying therapies in multiple sclerosis International Journal of Clinical Practice 2010 64 5 637 650
136. Harada J., Foley M., Moskowitz M. A., Waeber C., Sphingosine-1-phosphate induces proliferation and morphological changes of neural progenitor cells Journal of Neurochemistry 2004 88 4 1026 1039 (Pubitemid 38199325)
137. Allende M. L., Proia R. L., Sphingosine-1-phosphate receptors and the development of the vascular system Biochimica et Biophysica Acta 2002 1582 13 222 227 (Pubitemid 34634133)
138. Jolly P. S., Bektas M., Olivera A., Gonzalez-Espinosa C., Proia R. L., Rivera J., Milstien S., Spiegel S., Transactivation of sphingosine-1-phosphate receptors by Fc RI triggering is required for normal mast cell degranulation and chemotaxis Journal of Experimental Medicine 2004 199 7 959 970 (Pubitemid 38481087)
139. Donati C., Meacci E., Nuti F., Becciolini L., Farnararo M., Bruni P., Sphingosine 1-phosphate regulates myogenic differentiation: a major role for S1P2 receptor FASEB Journal 2005 19 3 449 451 (Pubitemid 40316546)
140. Krump-Konvalinkova V., Yasuda S., Rubic T., Makarova N., Mages J., Erl W., Vosseler C., Kirkpatrick C. J., Tigyi G., Siess W., Stable knock-down of the sphingosine 1-phosphate receptor S1P1 influences multiple functions of human endothelial cells Arteriosclerosis, Thrombosis, and Vascular Biology 2005 25 3 546 552 (Pubitemid 40315676)
141. Halin C., Scimone M. L., Bonasio R., Gauguet J. M., Mempel T. R., Quackenbush E., Proia R. L., Mandala S., Von Andrian U. H., The S1P-analog FTY720 differentially modulates T-cell homing via HEV: T-cell-expressed S1P1 amplifies integrin activation in peripheral lymph nodes but not in Peyer patches Blood 2005 106 4 1314 1322 (Pubitemid 41129595)
142. Tao R., Hoover H. E., Zhang J., Honbo N., Alano C. C., Karliner J. S., Cardiomyocyte S1P1 receptor-mediated extracellular signal-related kinase signaling and desensitization Journal of Cardiovascular Pharmacology 2009 53 6 486 494
143. Brinkmann V., Davis M. D., Heise C. E., Albert R., Cottens S., Hof R., Bruns C., Prieschl E., Baumruker T., Hiestand P., Foster C. A., Zollinger M., Lynch K. R., The immune modulator FTY720 targets sphingosine 1-phosphate receptors Journal of Biological Chemistry 2002 277 24 21453 21457 (Pubitemid 34952287)
144. Kataoka H., Sugahara K., Shimano K., Teshima K., Koyama M., Fukunari A., Chiba K., FTY720, sphingosine 1-phosphate receptor modulator, ameliorates experimental autoimmune encephalomyelitis by inhibition of T cell infiltration Cellular amp; Molecular Immunology 2005 2 6 439 448
145. Brinkmann V., FTY720 (fingolimod) in Multiple Sclerosis: therapeutic effects in the immune and the central nervous system British Journal of Pharmacology 2009 158 5 1173 1182
146. Mehling M., Lindberg R., Raulf F., Kuhle J., Hess C., Kappos L., Brinkmann V., Th17 central memory T cells are reduced by FTY720 in patients with multiple sclerosis Neurology 2010 75 5 403 410
147. Webb M., Tham C. S., Lin F. F., Lariosa-Willingham K., Yu N., Hale J., Mandala S., Chun J., Rao T. S., Sphingosine 1-phosphate receptor agonists attenuate relapsing-remitting experimental autoimmune encephalitis in SJL mice Journal of Neuroimmunology 2004 153 1-2 108 121 (Pubitemid 38950933)
148. Van Doorn R., Van Horssen J., Verzijl D., Witte M., Ronken E., Van Het Hof B., Lakeman K., Dijkstra C. D., Van Der Valk P., Reijerkerk A., Alewijnse A. E., Peters S. L. M., De Vries H. E., Sphingosine 1-phosphate receptor 1 and 3 are upregulated in multiple sclerosis lesions GLIA 2010 58 12 1465 1476
149. Rouach N., Pébay A., Mme W., Cordier J., Ezan P., Etienne E., Giaume C., Tencé M., S1P inhibits gap junctions in astrocytes: involvement of G and Rho GTPase/ROCK European Journal of Neuroscience 2006 23 6 1453 1464
150. Beutler E., Cladribine (2-chlorodeoxyadenosine) The Lancet 1992 340 8825 952 956
151. Carson D. A., Wasson D. B., Taetle R., Yu A., Specific toxicity of 2-chlorodeoxyadenosine toward resting and proliferating human lymphocytes Blood 1983 62 4 737 743 (Pubitemid 13008659)
152. Yates D., Multiple sclerosis: orally administered cladribine displays efficacy in multiple sclerosis trial Nature Reviews Neurology 2010 6 4 182
153. Giovannoni G., Cook S., Rammohan K., Rieckmann P., Srensen P. S., Vermersch P., Hamlett A., Viglietta V., Greenberg S., Sustained disease-activity-free status in patients with relapsing-remitting multiple sclerosis treated with cladribine tablets in the CLARITY study: a post-hoc and subgroup analysis The Lancet Neurology 2011 10 4 329 337
154. Giovannoni G., Comi G., Cook S., Rammohan K., Rieckmann P., Srensen P. S., Vermersch P., Chang P., Hamlett A., Musch B., Greenberg S. J., A placebo-controlled trial of oral cladribine for relapsing multiple sclerosis The New England Journal of Medicine 2010 362 5 416 426
155. Barten L. J., Allington D. R., Procacci K. A., Rivey M. P., New approaches in the management of multiple sclerosis Drug Design, Development and Therapy 2010 4 343 366
156. Minagar A., Alexander J. S., Sahraian M. A., Zivadinov R., Alemtuzumab and multiple sclerosis: therapeutic application Expert Opinion on Biological Therapy 2010 10 3 421 429
157. Offner H., Neuroimmunoprotective effects of estrogen and derivatives in experimental autoimmune encephalomyelitis: therapeutic implications for multiple sclerosis Journal of Neuroscience Research 2004 78 5 603 624 (Pubitemid 39657579)
158. Papenfuss T. L., Powell N. D., McClain M. A., Bedarf A., Singh A., Gienapp I. E., Shawler T., Whitacre C. C., Estriol generates tolerogenic dendritic cells in vivo that protect against autoimmunity Journal of Immunology 2011 186 6 3346 3355
159. Dinarello C. A., Anti-inflammatory agents: present and future Cell 2010 140 6 935 950
160. Natarajan C., Bright J. J., Peroxisome proliferator-activated receptor-gamma agonist inhibit experimental allergic encephalomyelitis by blocking IL-12 production, IL-12 signaling and Th1 differentiation Genes and Immunity 2002 3 2 59 70 (Pubitemid 38961111)
161. Kanakasabai S., Chearwae W., Walline C. C., Iams W., Adams S. M., Bright J. J., Peroxisome proliferator-activated receptor agonists inhibit T helper type 1 (Th1) and Th17 responses in experimental allergic encephalomyelitis Immunology 2010 130 4 572 588
162. Nikodemova M., Lee J., Fabry Z., Duncan I. D., Minocycline attenuates experimental autoimmune encephalomyelitis in rats by reducing T cell infiltration into the spinal cord Journal of Neuroimmunology 2010 219 1-2 33 37
163. Zabad R. K., Metz L. M., Todoruk T. R., Zhang Y., Mitchell J. R., Yeung M., Patry D. G., Bell R. B., Yong V. W., The clinical response to minocycline in multiple sclerosis is accompanied by beneficial immune changes: a pilot study Multiple Sclerosis 2007 13 4 517 526 (Pubitemid 46796512)
164. Brines M. L., Ghezzi P., Keenan S., Agnello D., De Lanerolle N. C., Cerami C., Itri L. M., Cerami A., Erythropoietin crosses the blood-brain barrier to protect against experimental brain injury Proceedings of the National Academy of Sciences of the United States of America 2000 97 19 10526 10531
165. Agnello D., Bigini P., Villa P., Mennini T., Cerami A., Brines M. L., Ghezzi P., Erythropoietin exerts an anti-inflammatory effect on the CNS in a model of experimental autoimmune encephalomyelitis Brain Research 2002 952 1 128 134 (Pubitemid 35279495)
166. Yuan R., Maeda Y., Li W., Lu W., Cook S., Dowling P., Erythropoietin: a potent inducer of peripheral immuno/inflammatory modulation in autoimmune EAE PLoS ONE 2008 3 4, e1924
167. Chen S. J., Wang Y. L., Lo W. T., Wu C. C., Hsieh C. W., Huang C. F., Lan Y. H., Wang C. C., Chang D. M., Sytwu H. K., Erythropoietin enhances endogenous haem oxygenase-1 and represses immune responses to ameliorate experimental autoimmune encephalomyelitis Clinical and Experimental Immunology 2010 162 2 210 223
168. Demjen D., Klussmann S., Kleber S., Zuliani C., Stieltjes B., Metzger C., Hirt U. A., Walczak H., Falk W., Essig M., Edler L., Krammer P. H., Martin-Villalba A., Neutralization of CD95 ligand promotes regeneration and functional recovery after spinal cord injury Nature Medicine 2004 10 4 389 395 (Pubitemid 38508517)
169. Pitti R. M., Marsters S. A., Lawrence D. A., Roy M., Kischkel F. C., Dowd P., Huang A., Donahue C. J., Sherwood S. W., Baldwin D. T., Godowski P. J., Wood W. I., Gurney A. L., Hillan K. J., Cohen R. L., Goddard A. D., Botstein D., Ashkenazi A., Genomic amplification of a decoy receptor for Fas ligand in lung and colon cancer Nature 1998 396 6712 699 703 (Pubitemid 29003951)
170. Hayashi S., Miura Y., Nishiyama T., Mitani M., Tateishi K., Sakai Y., Hashiramoto A., Kurosaka M., Shiozawa S., Doita M., Decoy receptor 3 expressed in rheumatoid synovial fibroblasts protects the cells against fas-induced apoptosis Arthritis and Rheumatism 2007 56 4 1067 1075 (Pubitemid 46608631)
171. Zhang J., Salcedo T. W., Wan X., Ullrich S., Hu B., Gregorio T., Feng P., Qi S., Chen H., Cho Y. H., Li Y., Moore P. A., Wu J., Modulation of T-cell responses to alloantigens by TR6/DcR3 Journal of Clinical Investigation 2001 107 11 1459 1468 (Pubitemid 32522040)
172. Yu K. Y., Kwon B., Ni J., Zhai Y., Ebner R., Kwon B. S., A newly identified member of tumor necrosis factor receptor superfamily (TR6) suppresses LIGHT-mediated apoptosis Journal of Biological Chemistry 1999 274 20 13733 13736
173. Sabelko-Downes K. A., Cross A. H., Russell J. H., Dual role for Fas ligand in the initiation of and recovery from experimental allergic encephalomyelitis Journal of Experimental Medicine 1999 189 8 1195 1205 (Pubitemid 29198258)
174. Chen S. J., Wang Y. L., Kao J. H., Wu S. F., Lo W. T., Wu C. C., Tao P. L., Wang C. C., Chang D. M., Sytwu H. K., Decoy receptor 3 ameliorates experimental autoimmune encephalomyelitis by directly counteracting local inflammation and downregulating Th17 cells Molecular Immunology 2009 47 2-3 567 574
175. Korn T., Pathophysiology of multiple sclerosis Journal of Neurology 2008 255 6 2 6
176. Komiyama Y., Nakae S., Matsuki T., Nambu A., Ishigame H., Kakuta S., Sudo K., Iwakura Y., IL-17 plays an important role in the development of experimental autoimmune encephalomyelitis Journal of Immunology 2006 177 1 566 573 (Pubitemid 43939170)
177. Steinman L., Mixed results with modulation of T H-17 cells in human autoimmune diseases Nature Immunology 2010 11 1 41 44
178. Murphy A. C., Lalor S. J., Lynch M. A., Mills K. H. G., Infiltration of Th1 and Th17 cells and activation of microglia in the CNS during the course of experimental autoimmune encephalomyelitis Brain, Behavior, and Immunity 2010 24 4 641 651
179. Fletcher J. M., Lalor S. J., Sweeney C. M., Tubridy N., Mills K. H. G., T cells in multiple sclerosis and experimental autoimmune encephalomyelitis Clinical and Experimental Immunology 2010 162 1 1 11
180. Lovett-Racke A. E., Yang Y., Racke M. K., Th1 versus Th17: are T cell cytokines relevant in multiple sclerosis? Biochimica et Biophysica Acta 2011 1812 2 246 251
181. Wang Y. L., Chou F. C., Sung H. H., Fan P. L., Hsueh C. W., Lin W. C., Chen S. J., Lin W. W., Sytwu H. K., Decoy receptor 3 protects non-obese diabetic mice from autoimmune diabetes by regulating dendritic cell maturation and function Molecular Immunology 2010 47 16 2552 2562
182. Naismith R. T., Piccio L., Lyons J. A., Lauber J., Tutlam N. T., Parks B. J., Trinkaus K., Song S. K., Cross A. H., Rituximab add-on therapy for breakthrough relapsing multiple sclerosis: a 52-week phase II trial Neurology 2010 74 23 1860 1867